Ligand

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF GLIOBLASTOMA

Retrieved on: 
Monday, January 9, 2023
Cancer, RAGE, Glioblastoma, HMGB1, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Receptor (biochemistry), Brain, Orphan, RAGE (receptor), Breast, HIV disease progression rates, Alzheimer's disease, Dementia, Breast cancer, S100, Patient, FDA, Ligand, S100 protein, Pancreatic cancer, Marketing, Pharmaceutical industry, Medical imaging

WESTON, Fla., Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.

Key Points: 
  • WESTON, Fla., Jan. 9, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of glioblastoma.
  • By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment.
  • "Receiving FDA orphan drug status for azeliragon highlights the significant unmet need for novel treatment options for patients with glioblastoma, the most common and lethal primary brain cancer," commented Stephen G. Marcus, M.D., Chief Executive Officer of Cantex.
  • FDA Orphan Drug Designation provides Cantex with seven years of azeliragon marketing exclusivity from the time of product launch for the orphan indication, and several other important benefits, including assistance in the drug development process, tax credits for clinical costs, and exemptions from certain FDA fees.

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

Retrieved on: 
Friday, January 6, 2023
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Novin, Molluscum contagiosum, Food, SB206, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, File, NDA, Nitric oxide, Trial of the century, Medicine, Investment, FDA, Pharmaceutical industry, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum).

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Novan, Inc. (Nasdaq: NOVN) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum (molluscum).
  • Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval.
  • “In 2019 Ligand provided funding to Novan for the clinical development of berdazimer gel in exchange for milestones and royalties.
  • If approved, berdazimer gel, 10.3% would be the first topical treatment indicated for molluscum with the convenience of self-application.

Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO - IO) Annual Congress

Retrieved on: 
Thursday, December 8, 2022
RNA, Immunotherapy, Annual report, Security (finance), SD, Ovarian cancer, Marketing, LILRB2, Hypothyroidism, Induction, Nivolumab, RO, Society for Immunotherapy of Cancer, Interval (mathematics), Clinical trial, Tumor microenvironment, Inflammation, Macrophage, Safety, Congress, Cancer, PD-1, Large-cell lung carcinoma, Gilead Sciences, Trae tha Truth, CI, PFS, PD-L1, Ligand, CCR8, NSCLC, SELECT, RECIST, ORR, Immune system, Patient, ILT4, Bone pain, ICOS, Poster, Immunoglobulin G, Pharmacokinetics, Toxic epidermal necrolysis, CD4, IO, Cachexia, Appendix, Therapy, Partnership, Pharmaceutical industry, Vaccine, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported new clinical data from the INNATE trial with JTX-8064 and pimi and the SELECT trial with vopra and pimi in two poster presentations at the ESMO-IO 2022 Annual Congress being held in Geneva, Switzerland.

Key Points: 
  • Pimivalimab is currently being assessed in the INNATE Phase 1/2 trial (NCT04669899) in combination with JTX-8064, a LILRB2 (ILT4) inhibitor.
  • Pimivalimab is also being assessed in the SELECT Phase 2 clinical trial (NCT04549025) in combination with vopratelimab.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Ligand Provides Highlights from its Investor and Analyst Day Event

Retrieved on: 
Tuesday, December 13, 2022
Professional Services, Health, FDA, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Water, Baxter International, Gilead Sciences, Security (finance), Molluscum contagiosum, NDA, Immunoglobulin A, EPS, Drug discovery, Partnership, EMA, ESG, Amgen, Element, Economics, FDA, Solubility, Pachyonychia congenita, Investment, Gilead, LBL, COVID-19, GAAP, Nevoid basal-cell carcinoma syndrome, News, Vaccine, IgA nephropathy, COPD, Social Security Government Pension Offset, MLM, Merck, Marketing, Forecasting, Social, Risk management, Fine chemical, Renewable energy, Pharmaceutical industry, Pfizer, COVID, Takeda, Ligand

Highlights of todays event held in-person in New York City and virtually included the following:

Key Points: 
  • Highlights of todays event held in-person in New York City and virtually included the following:
    Management reviewed Ligands business model and the ongoing diversification of its partnership portfolio.
  • Ligand shares in the promise of the biopharmaceutical industry through royalty economics earned from providing development capital and access to its platform technologies.
  • Today Ligand has economic rights to more than 100 programs being developed or commercialized by nearly 100 different partners.
  • Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.

Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum

Retrieved on: 
Wednesday, December 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Peptide, Therapy, Escient, Hives, CSU, Ligand, Itchy, Cytokine, Cold urticaria, Doctor of Philosophy, Skin, B cell, Patient, Translation (biology), Angioedema, Histamine, Chemokine, Pain, Sleep, MRGPRX4, Cholestatic pruritus, MRGPRX2, Tissue, Drug discovery, Atopic dermatitis, Pharmaceutical industry, Vaccine

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the companys EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the presentation of preclinical data related to the companys EP262 development program at the 6th GA2LEN Global Urticaria Forum being held in Berlin, Germany, December 7-8, 2022.
  • EP262, a potent, highly selective antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), represents a novel, targeted approach to the treatment of mast cell-mediated disorders.
  • In chronic inducible urticaria (CIndU), hives are induced by specific triggers such as cold exposure (cold urticaria) or touch (symptomatic dermographism), among others.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.

Kobe University research: Healthy gut, healthy heart: Gut bacteria and heart disease

Retrieved on: 
Friday, December 9, 2022
Water, Degenerative disease, AAA, Aorta, Ligand, Heart, Spleen, Immune system, Angiotensin, Development, Monocyte, Aortic rupture, Hypertension, Cardiac arrest, Bacteria, NOD1, Patient, Abdominal aortic aneurysm, Internal bleeding, Research, Injection, Cardiovascular disease, Incidence, Kobe University, Death, Bone marrow, AAAS, Tissue, Inflammation, Rupture, Stroke, Swelling, Risk, Pharmaceutical industry, Restaurant, Vaccine, Dietary supplement, Mouse

In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.

Key Points: 
  • In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
  • The composition of bacteria normally residing in the gut is known to play a role in other cardiovascular diseases.
  • The suppression of gut bacteria was, thus, somehow leading to a reduced risk of AAA.
  • This study revealed the link between gut bacteria and the onset of AAA.

Kobe University research: Healthy gut, healthy heart: Gut bacteria and heart disease

Retrieved on: 
Friday, December 9, 2022
Water, Degenerative disease, AAA, Aorta, Ligand, Heart, Spleen, Immune system, Angiotensin, Development, Monocyte, Aortic rupture, Hypertension, Cardiac arrest, Bacteria, NOD1, Patient, Abdominal aortic aneurysm, Internal bleeding, Research, Injection, Cardiovascular disease, Incidence, Kobe University, Death, Bone marrow, AAAS, Tissue, Inflammation, Rupture, Stroke, Swelling, Risk, Pharmaceutical industry, Restaurant, Vaccine, Dietary supplement, Mouse

In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.

Key Points: 
  • In a recent collaboration between Kobe University and the gut bacteriafocused company Noster Inc., a team led by Tomoya Yamashita has revealed the importance of gut bacteria in the development of AAA.
  • The composition of bacteria normally residing in the gut is known to play a role in other cardiovascular diseases.
  • The suppression of gut bacteria was, thus, somehow leading to a reduced risk of AAA.
  • This study revealed the link between gut bacteria and the onset of AAA.

Ligand Pharmaceuticals Names Director Todd C. Davis as CEO

Retrieved on: 
Monday, December 5, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Baxter International, Gilead Sciences, Apax Partners, Therapy, Security (finance), Net, Webcast, Laboratory, Q&A, Drug discovery, Harvard University, United States service academies, Amgen, Abbott Laboratories, Navy, Partner (business rank), Solubility, Investment, COVID-19, Growth, News, RSVP, Partner, Merck, Marketing, Sanofi, Management, Fine chemical, Pfizer, Takeda, Ligand, Vaxart

When the Board recruited John as CEO in 2006, Ligand was operating at a significant net loss and had fewer than 10 royalty assets.

Key Points: 
  • When the Board recruited John as CEO in 2006, Ligand was operating at a significant net loss and had fewer than 10 royalty assets.
  • Today Ligand has nearly 150 partnered drugs and drug candidates in various stages of commercialization and development.
  • Todd Davis has been actively involved in setting Ligands strategic direction, and we are fortunate he has agreed to serve as CEO.
  • Mr. Davis commented, I am honored to assume the day-to-day leadership of Ligand.

NETRIS Pharma Doses First Patient in Phase 2 Study of NP137 for Checkpoint Inhibitor Resistance

Retrieved on: 
Tuesday, November 29, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CFO, Immunoglobulin G, PD-1, Union, RECIST, Cell, Small and medium-sized enterprises, Cancer, SME, NCI-designated Cancer Center, OEIC, Patient, EIC, Transitional epithelium, Erosion (morphology), Organization, Instrument, Apoptosis, Uterine cancer, Ligand, Neoplasm, Netrin 1, Immunotherapy, Principal, Pharmaceutical industry, Medical imaging, Fine chemical, Melanoma

The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.

Key Points: 
  • The enrollment of the first patient in ImmunoNET is a new clinical milestone for NETRIS Pharma.
  • Based on a unique mode of action of NP137 and biomarker studies conducted in Phase 1, we believe we can enlarge the fraction of responding patients and potentially prevent resistance, said Patrick Mehlen, CEO of NETRIS Pharma.
  • ImmunoNET has been specifically designed by clinicians to provide new solutions for patients suffering from resistance to immune-checkpoint inhibitors.
  • NETRIS Pharma, a clinical-stage company designs and develops anti-cancer therapeutic molecules, particularly monoclonal antibodies, to block the interaction between dependence receptors and their ligands.

Ligand to Hold Investor and Analyst Day on December 13

Retrieved on: 
Wednesday, November 16, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Health Technology, Solubility, Drug discovery, Baxter International, Merck, Amgen, Gilead Sciences, St. Regis New York, Fine chemical, Takeda, Ligand, Pfizer

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time).

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time).
  • Presenters will include:
    Presentations by Ligand executives will address the following topics:
    Commentary on Ligands business model, financial outlook and capital deployment strategy
    The presentations will be followed by lunch for those attending in person.
  • Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
  • Ligand has established multiple alliances, licenses and other business relationships with leading pharmaceutical companies including Amgen, Merck, Pfizer, Takeda, Gilead Sciences and Baxter International.